The American Society for Virology invites you to participate in the 28th Annual Meeting being held at the picturesque Vancouver campus of the University of British Columbia. The 2009 ASV scientific program will include symposia and concurrent sessions on multiple aspects of virology.
HIV affects 33 million individuals worldwide. To date, 25 million have died from AIDS. In 2007 alone, 2.7 million persons became newly infected with HIV-1, and 2 million new AIDS deaths were registered. A quarter century after the discovery of the HIV-1 virus, a curative or a vaccine strategy for AIDS remains elusive. This conference will bring together leading human retrovirus researchers to review current progress and to chart future challenges. Internationally renowned speakers will present their insights into the principles guiding the life cycle of endogenous retroelements, complex human retroviruses, and their pathogenic interactions with the hosts.
http://www.amiando.com/frontiersofretrovirology.html
Tuberculosis (TB) is the largest cause of death in the AIDS setting, having caused approximately 50% of all AIDS deaths globally. Each infection on its own manipulates the host immune response to enhance the other infection’s pathogenicity, and the treatment of each involves long or lifelong therapy of complicated drug regimens. The focus of this Keystone Symposia meeting is to gain deeper insights into the immune pathology and deadly synergism between HIV and TB and its global toll in order to identify new ways to solve this global catastrophe by way of basic scientific discovery, and the development and delivery of vaccines, drugs and care. Mycobacterium tuberculosis survives in the vast majority of infected individuals without causing disease. However, as HIV compromises the immune system it fuels clinical emergence of TB and, as a result, has become the driving force for the current TB epidemics in Subsaharan Africa and Asia. TB in turn drives HIV-1 replication and causes HIV-1 disease progression. In order to effectively tackle this twin epidemic, integrated approaches encompassing basic immunological research, drug discovery, drug and vaccine design and delivery and novel approaches to delivering care in remote and impoverished areas must be integrated. This includes the following: virologic and bacteriologic research on the pathogens themselves; immunologic, molecular and cellular research on the host response; design, development and delivery of drugs and vaccines; development of different technologies for biomarkers of disease and cure; and novel drug and vaccine delivery systems. Moreover, basic discovery must be synergized with novel approaches to the delivery of TB and AIDS care in endemic areas. The overarching goal of the symposium is to gain a broad perspective on the problem of TB/AIDS – from its impact on life on earth to the basic biology of the organisms, the immune response – and to develop new paradigms of thinking and responses to deal with the humanitarian catastrophe of TB and AIDS co-infection.
http://keystonesymposia.org/Meetings/ViewMeetings.cfm?MeetingID=1022
We are pleased to announce that the 10th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms will be held November 15-18, 2009, at the Wyndham Virginia Crossings Hotel and Conference Center in Richmond, Virginia.
http://antiviralresistance.org/
The 11th International Hepatitis C Conference will be a three day event with a full programme of international speakers and oral abstract presentations. The conference will be held in the UK at the Lowry Hotel Manchester on the 16th-18th November 2009.
The Keystone Symposia Meeting on HIV Biology and Pathogenesis emphasizes key aspects of the basic virological, cell and molecular biological, and disease aspects of HIV. The focus will be to highlight recent advances in our understanding of HIV/AIDS ranging from the earliest events of transmission, to treatments for infected individuals, to interventions to prevent viral transmission. The goal of the meeting is to emphasize the basic mechanisms of viral replication and the interplay of the virus with the immune system leading to the development of AIDS.
http://keystonesymposia.org/Meetings/viewMeetings.cfm?MeetingID=1053
The Keystone Symposia meeting on the Cell Biology of Virus Entry, Replication and Pathogenesis emphasizes key aspects of virus infection pathways and cellular responses. A central goal is the identification of critical virus-cell crosstalk during these processes. Rather than dividing viruses into separate “categories” such as positive-sense RNA viruses and DNA viruses, the meeting highlights common aspects of virus lifecycles among different virus groups. The multi-disciplinary nature of the proposed meeting is important in bringing together investigators using structural, molecular, cell biological, immunological and epidemiological methods. This emphasis on shared themes and multiple experimental approaches will continue to be critical to future advances in virology. While there has been spectacular recent progress in our understanding of virus lifecycles, we are still very far from being able to design antiviral strategies, and unexpected novel aspects of virus cell biology are constantly being discovered. Plenary sessions will cover the most important aspects of virus interactions with cells. Day 1 will include cutting-edge structural virology studies and imaging methods to follow single virus particles during entry. Day 2 will focus on the entry mechanisms of enveloped and non-enveloped viruses and the roles of cellular proteins in virus infection. Day 3 will cover viral and cellular aspects of virus replication and cellular antiviral responses. The last day will focus on the important areas of virus assembly and pathogenesis. Late-breaking exciting developments in this fast-moving field will be incorporated by short presentations and afternoon workshop sessions drawn from the submitted abstracts.
http://keystonesymposia.org/Meetings/viewMeetings.cfm?MeetingID=1049
The EMBO World Lecture Course will focus on recent progress made in examining the interplay between some well-studied plant and animal viruses and their hosts.
http://cwp.embo.org/wlc10-01/index.html
Traditionally, the Keystone Joint HIV Symposia have integrated vaccines and pathogenesis to comprehensively cover the field—from HIV’s fundamental biology to its interaction with the human immune system and how to design a vaccine—and these Joint Symposia have been convened every year. In addition to this Keystone Joint Symposium, there are a couple of other well-established HIV vaccine meetings in the year (CROI and the AIDS Vaccine Conference) that follow a similar format and also often feature a similar line-up of speakers. Since an HIV vaccine is proving to be a particularly recalcitrant problem, a novel approach that facilitates a wider cross-fertilization of ideas would be very valuable and would be welcomed by the broader HIV vaccine research community. To that end, the major development proposed for the 2010 Keystone HIV Vaccine Symposium is to foster innovative ideas and new collaborations with immunology and vaccinology as it pertains to other viral diseases. Specifically, we propose that a new Joint Symposium of HIV Vaccines in conjunction with Viral Immunity be convened. This Joint Symposium would retain the valuable format that includes joint and separate sessions covering general and specific principles.
http://keystonesymposia.org/Meetings/viewMeetings.cfm?MeetingID=1051
The most exciting recent advances in viral immunity include the increased understanding of the role of innate immune mechanisms, interaction between innate and adaptive immunity, pathogen manipulation of host responses, and activation of immune responses and generation of immune memory. Despite these advances, basic mechanisms of anti-viral immunity are poorly characterized particularly for chronic infections. Efforts are also required to exploit recent research advances to improve vaccine design and therapeutic intervention. This meeting will include both innate and adaptive immunity and juxtapose animal models with human studies as it attempts to foster collaborative efforts between attending viral immunologists and the HIV vaccine researchers in the joint meeting. Expert talks in plenary sessions will encompass the latest in critical areas of viral immunity. Workshops and additional presentations will cover provocative and cutting-edge results from attendees. The meeting objective is to accelerate progress in understanding and manipulating anti-viral immunity to improve human health.
http://keystonesymposia.org/Meetings/viewMeetings.cfm?MeetingID=1050
The 16th ISHEID congress is an ideal opportunity to network and to increase and update your knowledge ! Come to Marseille from 24 to 26 March 2009 to listen to the renowned International Leaders in the fields of HIV and Hepatitis Viruses give you State-of-the-Art Lectures.
The 16th ISHEID congress is the major International Conference specifically designed by scientists to give specialists an opportunity to :
- receive high quality scientific information
- meet in a friendly atmosphere
- and give you practical information for everyday use
http://www.isheid.com/site/-10ISHEID,671-?lang=eng
The congress will be the annual meeting of the European Society for Clinical Virology, the German/Swiss/Austrian Society for Virology (Gesellschaft fϋr Virologie) and the Italian Society of Virology.
The Eurovirology Congresses, renamed European Virology Congresses, were initiated in 2000 to bring together young and senior investigators from all Countries of Europe and from all branches of Virology. The aim was to strengthen Virology in Europe, by providing a platform for basic, medical, clinical, veterinary, and plant Virology. Congresses were held sequentially in UK, Spain and Germany. Importantly, they have fostered the foundation of the European Society for Virology (www.eusv.eu), the inaugural meeting of which will be held in Rome, April 24, 2009.
The Venue is the beautiful Spazio Congressi Villa Erba, Cernobbio, Lake of Como. This is one of Italy's most enchanting corners. Cernobbio, very close to Como, dominates the west side of the lake and offers a breathtaking view of miles of the lake. Lake Como has always been and still is a world famous international resort. Visitors are enraptured by its charming atmosphere and natural beauty. Cernobbio-Como are 50 Km away from the Malpensa Airport, the main airport in Northern Italy.
http://www.eurovirology2010.org/
It is an exciting time for the field of HCV antivirals. Viral protease and polymerase inhibitors are in late stage clinical trials, as are combinations of them, suggesting an interferon-free drug cocktail to treat HCV may one day be possible. Progress is also being made on small molecule drug candidates that inhibit host proteins involved in the maturation/processing of HCV particles.
Join fellow drug discovery chemists for one and a half days of presentations, posters, roundtable and panel discussions plus plenty of networking time to stay abreast of this burgeoning area and hear the latest medicinal chemistry optimizations and clinical trial strategies and progress of small molecule drug candidates targeting HCV infection.
Topics Presented:
http://www.drugdiscoverychemistry.com/dch/hcv
IFRRS is a bi-annual conference that focuses on the latest advances in genomics, immunology, and infectious disease as well as gene therapy, anti-viral therapy and vaccine development from the perspective of feline health and the potential translational applications to human health. The goal of the symposium is to provide a forum for participants to share cutting-edge data and ideas and to foster collaborative efforts to improve feline and human health.
The symposium attracts a diverse attendance from academia, industry, and clinical specialists. There is no other conference that brings together renowned experts from the international scientific community involved in retroviral research employing the feline model.
The second ESF-EMBO symposium on "Applications of antiviral RNA interference (RNAi)" will be held in the early summer of 2010 (May 30 – June 4, 2010) in Sant Feliu de Guixols at the Costa Brava in Spain. Some 100 participants are expected to come together from the fields of RNAi research and virology to present their latest findings on RNAi-virus interactions, as well as the progress in the development of RNAi-based antiviral therapeutics. One of the big questions that will be addressed concerns the role of RNAi in natural antiviral defence mechanisms in mammals. In addition, new solutions to improve the efficacy and safety of RNAi-based antiviral drugs will be presented. The combined expertise of researchers studying RNAi in plants, insects and mammalian systems is supposed to greatly stimulate the overall discussion.
http://www.esf.org/index.php?id=6439
In Bruges this scientific sessions will be held at the Concertgebouw. The posters and talks will review all recent developments in basic research on negative strand viruses, including progress in high resolution structure determination, the control of negative strand viral RNA synthesis, and the cellular innate response to negative strand virus infection etc.
http://sites.google.com/site/nsv2010mtg/home
Given recent major discoveries in the domain of viruses infecting Archaea, Bacteria and unicellular Eukaryotes (Protists), we are convinced that a gathering of these different scientific communities would be a timely and productive endeavour for unifying the knowledge on different groups of viruses into a consistent picture, filling the gap that presently divides scientists working on prokaryotic and eukaryotic viruses and helping to form a cohesive view of the viral world.
This First International Congress on Virus of Microbes marks a new era in viral research, which has begun with the recognition that viruses are the predominant component of the biosphere numerically, with a considerable impact on the planet’s ecology, and represent the greatest genetic resource in the biosphere, significantly affecting biosystem’s evolution.
At the meeting will be highlighted global aspects of problems concerning the diversity, ecology, and environmental impact of viruses infecting Bacteria, Archaea and microbial Eukaryotes. Actively will be discussed also problems of the origin and nature of viruses, and their role in early life evolution.
Particular attention will also be given to technological and medical applications of microbial viruses, including their exploitation in “phage display” studies, their potential in developing new advanced materials for nanotechnology, and their medical application.
The topics considered at the congress will be covered in the following 5 scientific sessions:
http://www.pasteur.fr/infosci/conf/VirusMicrobes2010/
The American Society for Virology (ASV) was founded in 1981 to provide a forum for investigators of human, animal, insect, plant, fungal and bacterial viruses, whether the research involves the use of clinical, ecological, biological or biochemical approaches. The Society sponsors an annual meeting, designed to promote discussion and collaboration among scientists active in all aspects of virology.
AIDS 2010 will mark an important milestone: the deadline by which world leaders have committed to ensuring universal access to HIV prevention, treatment, care and support. The conference will be an opportunity to evaluate progress to date and to identify what must be done, both individually and collectively, to achieve this critical goal. With an estimated 25,000 participants and 2,500 media in attendance, the eyes of the world will be upon Vienna.
Antiviral Research, the most comprehensive and pre-eminent journal for those interested in the effective control of virus infections in animals and humans, as well as in plants and lower organisms, will celebrate its 30th anniversary in 2010. To celebrate this anniversary, the Editors and the Publisher of the journal are delighted to announce an 'Antivirals Congress', to be held in Amsterdam in November 2010. The key objectives of the congress are:
The congress will serve as an interface between academics, those in research and development, regulatory and governmental agencies, charities, and health and industry professionals.
Attendance at this conference will enable you to:
To supplement a number of invited keynote presentations, contributions are invited for oral and poster presentations on the following topics:
http://www.antivirals.elsevier.com/
